Wasatch Advisors Inc Esperion Therapeutics, Inc. Transaction History
Wasatch Advisors Inc
- $20.1 Billion
- Q3 2024
A detailed history of Wasatch Advisors Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Wasatch Advisors Inc holds 23,346,013 shares of ESPR stock, worth $51.1 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
23,346,013
Previous 16,862,943
38.45%
Holding current value
$51.1 Million
Previous $37.4 Million
2.9%
% of portfolio
0.19%
Previous 0.2%
Shares
30 transactions
Others Institutions Holding ESPR
# of Institutions
206Shares Held
128MCall Options Held
1.67MPut Options Held
930K-
Black Rock Inc. New York, NY14MShares$30.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$28.6 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$21.8 Million0.28% of portfolio
-
Two Seas Capital LP Rye, NY6.58MShares$14.4 Million3.65% of portfolio
-
Geode Capital Management, LLC Boston, MA4.33MShares$9.49 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $146M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...